+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06160206

Phase II Study of Retifanlimab Combined with Bevacizumab and Hypofractionated Radiotherapy for Adults with Recurrent Glioblastoma

Led by Academic and Community Cancer Research United · Updated on 2024-11-19

134

Participants Needed

3

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of combining retifanlimab with bevacizumab and hypofractionated radiation therapy HFRT compared to bevacizumab and HFRT alone in patients with recurrent glioblastoma, a type of aggressive brain tumor that has returned after prior improvement. This phase II trial aims to assess overall survival at 9 months and other outcomes such as progression-free survival, objective response rate, neurological function, and treatment side effects. The study also investigates immune responses related to retifanlimab treatment. Participants are randomly assigned to one of two groups. One group receives retifanlimab intravenously on day 1 and bevacizumab intravenously on days 1 and 15 of each 28-day cycle, plus daily HFRT starting on day 15 for 10 treatments. The other group receives bevacizumab on the same schedule and identical HFRT. Treatment may continue for up to 2 years if there is no disease progression or unacceptable side effects. Throughout the study, participants undergo MRI or CT scans and blood sample collections. After completing treatment, participants have a follow-up visit at 30 days. Survival is monitored every 2 months for the first year and then every 6 months for up to 4 years from registration. Researchers measure survival times, tumor progression, neurological function, response rates, and adverse events. They also examine immune system changes before and after treatment. The total participation duration can last several years depending on survival and follow-up.

CONDITIONS

Brief Title

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Research Team

I

Inbox Mayo Clinic Cancer Studies

M

Mayo Clinic Cancer Studies

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here